Metabolic Medicine and Prevention
Metabolic health does not begin with the diagnosis — it begins with the conversation before it.
The metabolic syndrome is not a single disease — it is a cascade. Obesity and insulin resistance, the body’s diminishing ability to regulate blood sugar effectively, create an internal environment in which glucose and fat metabolism fall out of balance. Over time, this imbalance takes on a life of its own: metabolic fatty liver disease (MASLD), fat deposition in the pancreas (pancreatic lipomatosis), diabetes (type 2), cardiovascular and kidney disease, and in some cases dementia. The effects reach the whole body, not just a single organ. A growing number of people are living with obesity. At the same time, the understanding is growing that weight is not simply a matter of willpower, but a complex interplay of biology, life circumstances, and psychology.
What matters most to me in treatment is this: intervention is possible at every stage. Many of these processes are reversible, often far more so than patients expect. Prevention, to my mind, means understanding early what is already under way in the body, and together setting a different course before the cascade takes on a life of its own.
My approach is holistic care across the full health continuum: nutrition, movement, psychological factors, and pharmacological support where it is warranted. Medication alone is rarely the whole answer: I work with a network of specialists in exercise training, nutritional counselling, and psychological support to enable lasting change. I care for not only those with established conditions, but also those who want to shape their health proactively, and who ask what is necessary today to still be doing what matters to them at ninety.
Heart, vessels and kidneys
The heart, the kidneys, and metabolism often fall ill together. Since 2023 there has been a term for this: cardiovascular-kidney-metabolic syndrome (CKM syndrome), the interplay of excess weight, raised blood sugar, high blood pressure, and raised blood lipids with diseases of the heart, the blood vessels, and the kidneys. Anyone who looks at one organ alone easily overlooks the others, the kidneys above all. Declining kidney function causes no symptoms for a long time, yet it can be detected early, with a blood value from which the filtration rate is calculated (creatinine) and a urine sample tested for protein (albumin). That is why both are part of my metabolic assessment. With blood lipids I look beyond LDL cholesterol: in the metabolic syndrome, LDL particles are often small and dense. The usual value then underestimates the risk; apolipoprotein B (ApoB) captures it more accurately. The syndrome is classified in stages, and at each of them it can be countered; some changes can even be reversed. Which steps make sense is something we decide together; in special situations I coordinate with colleagues in heart and kidney medicine.
Medication-assisted weight loss
Pharmacological weight medicine has changed fundamentally within a few years. A new generation of agents mimics the body’s own gut hormones that regulate satiety and blood sugar (known as incretin-based therapies: GLP-1 and GIP receptor agonists). In the media they are usually called “weight-loss injections” — a phrase that shortens the story, but these are the substances it refers to. With my patients I mostly use tirzepatide, which acts on two of these hormone systems at once; semaglutide and other substances have their place as well, and the choice depends on the individual profile and accompanying conditions. Honesty matters to me here: these medications regulate appetite and satiety, they do not replace change, and after stopping them, weight often returns without an accompanying shift in lifestyle. That is why, in my care, they remain embedded in nutrition, movement, and psychological support. Development continues at pace: agents such as orforglipron in tablet form or retatrutide with three hormonal targets are currently in clinical trials and not yet approved. I follow these developments closely in order to advise on a sound footing.
Brain and memory
The brain, too, is part of the metabolic cascade. High blood pressure, diabetes (type 2), obesity, and raised blood lipids (LDL cholesterol) in midlife are among the factors that increase the risk of dementia later in life. One important route runs through the blood vessels: what harms the heart often harms the fine vessels of the brain as well. An increased risk is not destiny, and no one can prevent dementia with certainty. Part of the risk can nevertheless be influenced; the evidence is strongest for the treatment of high blood pressure. For me, brain health is therefore part of metabolic care: one more good reason to take blood pressure, blood sugar, and blood lipids seriously early on and to keep moving, long before memory becomes a concern.
What I offer
Metabolic health assessment
Evaluation of individual metabolic risk with blood glucose and insulin status, an extended lipid profile (including apolipoprotein B), liver and kidney values (filtration rate, urine albumin), and anthropometric measurements
Cardiovascular risk
Assessment of individual risk, including where there is a family history, and targeted treatment of the modifiable factors (lipids, blood pressure, blood glucose, weight)
Weight medicine
Support for obesity and weight reduction: individualised combination of lifestyle modification, nutritional counselling, and pharmacological support (tirzepatide, semaglutide)
Understanding your results together
Explanation of laboratory and imaging findings in clear, accessible language
Setting personal health goals
Shared development of realistic health targets: what do I want to still be doing at ninety — and what is required today to get there?
Interdisciplinary care
Collaboration with selected specialists in exercise training, psychology, and nutrition
Pharmacological support
Medication-based management of
- obesity: GLP-1/GIP agonists (tirzepatide, semaglutide)
- metabolic fat deposition in the liver (fatty liver, MASLD) and pancreas (pancreatic lipomatosis)
- diabetes (type 2): oral antidiabetics, injectable therapies (GLP-1/GIP agonists, insulin)
- lipid metabolism disorders: statins, ezetimibe, bempedoic acid, PCSK9 inhibitors